APLS
Price
$36.83
Change
+$1.20 (+3.37%)
Updated
Sep 19, 09:56 AM (EDT)
46 days until earnings call
FOLD
Price
$11.07
Change
+$0.16 (+1.47%)
Updated
Sep 19, 10:16 AM (EDT)
47 days until earnings call
Ad is loading...

APLS vs FOLD

Header iconAPLS vs FOLD Comparison
Open Charts APLS vs FOLDBanner chart's image
Apellis Pharmaceuticals
Price$36.83
Change+$1.20 (+3.37%)
Volume$2.11K
CapitalizationN/A
Amicus Therapeutics
Price$11.07
Change+$0.16 (+1.47%)
Volume$1.12K
CapitalizationN/A
View a ticker or compare two or three
APLS vs FOLD Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
APLS vs. FOLD commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and FOLD is a Sell.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (APLS: $35.64 vs. FOLD: $10.91)
Brand notoriety: APLS and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 51% vs. FOLD: 109%
Market capitalization -- APLS: $4.34B vs. FOLD: $3.24B
APLS [@Biotechnology] is valued at $4.34B. FOLD’s [@Biotechnology] market capitalization is $3.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while FOLD’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 5 bearish.
  • FOLD’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than FOLD.

Price Growth

APLS (@Biotechnology) experienced а -7.09% price change this week, while FOLD (@Biotechnology) price change was -3.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.81%. For the same industry, the average monthly price growth was +7.77%, and the average quarterly price growth was +2.01%.

Reported Earning Dates

APLS is expected to report earnings on Nov 04, 2024.

FOLD is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Biotechnology (+7.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($4.34B) has a higher market cap than FOLD($3.24B). FOLD YTD gains are higher at: -23.115 vs. APLS (-40.461). FOLD has higher annual earnings (EBITDA): -40.33M vs. APLS (-298.3M). APLS has more cash in the bank: 360M vs. FOLD (260M). FOLD has less debt than APLS: FOLD (444M) vs APLS (475M). APLS has higher revenues than FOLD: APLS (629M) vs FOLD (456M).
APLSFOLDAPLS / FOLD
Capitalization4.34B3.24B134%
EBITDA-298.3M-40.33M740%
Gain YTD-40.461-23.115175%
P/E RatioN/AN/A-
Revenue629M456M138%
Total Cash360M260M138%
Total Debt475M444M107%
FUNDAMENTALS RATINGS
APLS vs FOLD: Fundamental Ratings
APLS
FOLD
OUTLOOK RATING
1..100
6775
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
8691
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8156
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (77) in the Medical Distributors industry is in the same range as FOLD (81) in the Biotechnology industry. This means that APLS’s stock grew similarly to FOLD’s over the last 12 months.

APLS's Profit vs Risk Rating (86) in the Medical Distributors industry is in the same range as FOLD (91) in the Biotechnology industry. This means that APLS’s stock grew similarly to FOLD’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as FOLD (98) in the Biotechnology industry. This means that APLS’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Price Growth Rating (56) in the Biotechnology industry is in the same range as APLS (81) in the Medical Distributors industry. This means that FOLD’s stock grew similarly to APLS’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that FOLD’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSFOLD
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 11 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PWEAX13.07N/A
N/A
PACE International Em Mkts Eq A
WFDSX32.41N/A
N/A
Allspring SMID Cap Growth Fund - Cl Inst
ECERX21.74-0.04
-0.18%
Eaton Vance Stock C
IFUTX27.20-0.09
-0.33%
Invesco Dividend Income R6
FFPNX63.97-0.28
-0.44%
American Funds New Perspective 529-F-2

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ZYME. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+0.31%
ZYME - APLS
37%
Loosely correlated
+1.79%
RPHM - APLS
36%
Loosely correlated
+7.91%
AXON - APLS
33%
Loosely correlated
+0.15%
ORMP - APLS
33%
Poorly correlated
-3.59%
FOLD - APLS
33%
Poorly correlated
-2.59%
More

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-2.59%
RCKT - FOLD
53%
Loosely correlated
-4.40%
NTLA - FOLD
50%
Loosely correlated
-0.13%
DNLI - FOLD
49%
Loosely correlated
+0.26%
ROIV - FOLD
47%
Loosely correlated
-0.41%
BBIO - FOLD
46%
Loosely correlated
-2.88%
More